Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial

[1]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[2]  M. Stoel,et al.  Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial , 2017, JAMA cardiology.

[3]  J. W. Louwerenburg,et al.  Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial , 2016, The Lancet.

[4]  P. Serruys,et al.  Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  J. McMurray,et al.  Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure: A Systematic Review , 2016, Circulation. Heart failure.

[6]  L. Räber,et al.  External validity of the “all-comers” design: insights from the BIOSCIENCE trial , 2016, Clinical Research in Cardiology.

[7]  D. Shaw.  HEAT-PPCI sheds light on consent in pragmatic trials , 2014, The Lancet.

[8]  Mike Fisher,et al.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial , 2014, The Lancet.

[9]  S. Kaul,et al.  The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). , 2013, Journal of the American College of Cardiology.

[10]  David Moher,et al.  Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane reviewa , 2012, Systematic Reviews.

[11]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[12]  Gordon H Guyatt,et al.  Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review , 2012, BMJ : British Medical Journal.

[13]  P. Serruys,et al.  Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. , 2011, European heart journal.

[14]  G. Guyatt,et al.  GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.

[15]  Fredrik Folke,et al.  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.

[16]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.

[17]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.

[18]  P. Kirchhof,et al.  Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting , 2009, Thrombosis and Haemostasis.

[19]  F. Eberli,et al.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.

[20]  Richard Beasley,et al.  External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? , 2006, Thorax.

[21]  M. Simoons,et al.  Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. , 2006, European heart journal.

[22]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[23]  Kenneth F Schulz,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Exclusions before Randomisation Exclusions after Randomisation Sample Size Slippages in Randomised Trials: Exclusions and the Lost and Wayward , 2022 .